{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:01:18Z","timestamp":1779922878126,"version":"3.53.1"},"reference-count":52,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long\u2010term efficacy and safety of daclatasvir\u2010based regimens administered during clinical studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients enrolled within 6\u00a0months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow\u2010up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non\u2010responders or responders who relapsed, and characterization of liver disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir\u2010based regimens (follow\u2010up cut\u2010off, 13 October 2015); 60% were male, 18% aged \u226565\u00a0years, 87% had genotype\u20101a (42%) or \u20101b (45%) infection, and 18% had cirrhosis. Median follow\u2010up from parent study follow\u2010up Week 12 was 111 (range, 11\u2010246) weeks. 1329\/1489 evaluable patients were SVR12 responders; 1316\/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n\u00a0=\u00a09) or after (n\u00a0=\u00a03) parent study follow\u2010up Week 24; one was reinfected. Relapse occurred in 3\/842 (0.4%) and 9\/487 (2%) responders treated with interferon\u2010free or interferon\u2010containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non\u2010responders, emergent non\u2010structural protein\u20105A (NS5A) and \u20103 (NS3) substitutions were replaced by wild\u2010type sequences in 27\/157 (17%) and 35\/47 (74%) patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SVR12 was durable in 99% of recipients of daclatasvir\u2010based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non\u2010responders.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13596","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T14:26:38Z","timestamp":1506003998000},"page":"821-833","source":"Crossref","is-referenced-by-count":20,"title":["Long\u2010term follow\u2010up of clinical trial patients treated for chronic HCV infection with daclatasvir\u2010based regimens"],"prefix":"10.1111","volume":"38","author":[{"given":"K. Rajender","family":"Reddy","sequence":"first","affiliation":[{"name":"School of Medicine University of Pennsylvania  Philadelphia PN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-9591","authenticated-orcid":false,"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"H\u00f4pital Cochin  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Thuluvath","sequence":"additional","affiliation":[{"name":"Mercy Medical Center  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Toranomon Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Toyota","sequence":"additional","affiliation":[{"name":"Sapporo\u2010Kosei General Hospital  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[{"name":"Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Levin","sequence":"additional","affiliation":[{"name":"Dean Foundation  Madison WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Texas Liver Institute University of Texas Health Sciences Center  San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gadano","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Ghesquiere","sequence":"additional","affiliation":[{"name":"Vancouver Island Health Authority University of British Columbia  Victoria BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[{"name":"University of Duisburg\u2010Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia R.","family":"Brunetto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-6086","authenticated-orcid":false,"given":"Cheng\u2010Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"School of Medicine China Medical University  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Silva","sequence":"additional","affiliation":[{"name":"Hospital Universitario Austral  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[{"name":"College of Medicine Medical Research Institute Pusan National University Hospital Pusan National University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Wallingford CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Hopewell NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Wallingford CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misti","family":"Linaberry","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Noviello","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.Recommendations for testing managing and treating hepatitis C.http:\/\/wwwhcvguidelines org\/full\u2010report\u2010view. Accessed September 1 2017."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)01471-9"},{"key":"e_1_2_9_6_1","unstructured":"European Medicines Agency.Daklinza (daclatasvir) summary of product characteristics(updated 19\u2010September\u20102016)."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13264"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.826189"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13379"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28473"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28446"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312444"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"issue":"1","key":"e_1_2_9_16_1","first-page":"314A","article-title":"Daclatasvir plus sofosbuvir with or without ribavirin in genotype\u20103 patients from a large French multicenter compassionate use program","volume":"62","author":"Hezode C","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28632"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28535"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.029"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.019"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.004"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.10.010"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2013.7.4.458"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12350"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22694"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.034"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.043"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24663"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.019"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1500"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.014"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27113"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12964"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.018"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307498"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70138-X"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.007"},{"key":"e_1_2_9_50_1","first-page":"834","article-title":"Daclatasvir and peginterferon\/ribavirin for black\/african\u2010american and latino patients with HCV infection","volume":"15","author":"Rodriguez\u2010Torres M","year":"2016","journal-title":"Ann Hepatol"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2985"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i12.3418"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3177"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:57:58Z","timestamp":1695538678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/liv.13596"],"URL":"https:\/\/doi.org\/10.1111\/liv.13596","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}